Author: Brian Anderson

PKPD Explorations Using Paracetamol; 20 years on

Brian Anderson
University of Auckland

Paracetamol (acetaminophen) has served as a useful substrate for population modelling and factors determining dose. This modelling has improved not only PKPD understanding of the drug, but has also been useful to explore models that characterize size (e.g., allometry), clearance maturation, the impact of birth on clearance, the role of fat mass, concentration-response relationships, delayed […]

Read More

Alphaxalone Anaesthesia PKPD

Colin Goodchild (1), Juliet Serrao (1), John Sear (2), and Brian J Anderson (3)
1. Drawbridge Pharmaceuticals Pty Ltd, Victoria, Australia 2. Nuffield Dept of Anaesthetics, University of Oxford, UK 3. Dept of Anaesthesiology, University of Auckland, NZ

Background  Alphaxalone is an intravenous anaesthetic that has been formulated for human use as Phaxan™, an aqueous solution of alphaxalone 10 mg mL-1 and 13% betadex.  This study assessed the pharmacokinetic-pharmacodynamic (PKPD) characteristics of alphaxalone (Phaxan™) in humans. Methods: Alphaxalone 0.5 (0.42-0.55) [mean (range); mg kg-1] was given by single intravenous bolus injection of Phaxan™ to […]

Read More